Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Financial toxicity in hematological malignancies: a systematic review.
Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin GR. Ouchveridze E, et al. Among authors: mian h. Blood Cancer J. 2022 Apr 22;12(4):74. doi: 10.1038/s41408-022-00671-z. Blood Cancer J. 2022. PMID: 35459862 Free PMC article.
Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database.
McCurdy A, Louzada M, Venner CP, Visram A, Masih-Khan E, Kardjadj M, Jimenez-Zepeda VH, LeBlanc R, Sebag M, Song K, White D, Mian H, Stakiw J, Reiman A, Aslam M, Kotb R, Gul E, Reece D. McCurdy A, et al. Among authors: mian h. EJHaem. 2022 Aug 31;3(4):1252-1261. doi: 10.1002/jha2.559. eCollection 2022 Nov. EJHaem. 2022. PMID: 36467802 Free PMC article.
Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis.
LeBlanc R, Mian H, Reece D, Su J, Masih-Khan E, Chu M, Jimenez-Zepeda V, Sebag M, Song K, Louzada M, Kotb R, Visram A, White D, Stakiw J, Reiman A, Aslam M, Bergstrom D, Kaedbey R, Gul E, Venner C. LeBlanc R, et al. Among authors: mian h. Eur J Haematol. 2023 Nov;111(5):815-823. doi: 10.1111/ejh.14082. Epub 2023 Aug 13. Eur J Haematol. 2023. PMID: 37574220
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.
Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Pasvolsky O, et al. Among authors: mian h. Bone Marrow Transplant. 2022 Jan;57(1):31-37. doi: 10.1038/s41409-021-01455-y. Epub 2021 Oct 4. Bone Marrow Transplant. 2022. PMID: 34608275 Free PMC article.
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.
Tan CR, Estrada-Merly N, Landau H, Lekakis L, Banerjee R, Mian H, Usmani SZ, Hanbali A, Lazarus HM, Kyle RA, Dholaria B, Bal S, Strouse C, Murthy HS, Wirk B, Nishihori T, Kumar S, Shah N, Qazilbash M, D'Souza A. Tan CR, et al. Among authors: mian h. Bone Marrow Transplant. 2022 Feb;57(2):295-298. doi: 10.1038/s41409-021-01527-z. Epub 2021 Nov 20. Bone Marrow Transplant. 2022. PMID: 34802047 Free PMC article. No abstract available.
Outcomes after autologous hematopoietic cell transplantation in POEMS syndrome and comparison with multiple myeloma.
Kansagra A, Dispenzieri A, Fraser R, Estrada-Merly N, Sidana S, Nishihori T, Hansen DK, Anderson LD Jr, Banerjee R, Bumma N, Dhakal B, Khouri J, Landau H, Lee C, Mian H, Nathan S, Savani B, Kumar S, Qazilbash M, Shah N, D'Souza A. Kansagra A, et al. Among authors: mian h. Blood Adv. 2022 Jul 12;6(13):3991-3995. doi: 10.1182/bloodadvances.2022007218. Blood Adv. 2022. PMID: 35507742 Free PMC article. No abstract available.
109 results